Sk Chemicals Co., Ltd.

Tiumbio Co., Ltd.

Euisun Park

Hyun Jung Lee

Jae-Sun Kim

Bong-Yong Lee

Hun-Taek Kim

Jaeseung Ahn

So-young Lee

Ju Young Lee

Hyun-Jung Lee

Dong Chul Shin

Seon-Mi Kim

Jung A Lee

Je Ho Ryu

Keun-Ho Ryu

Young-Ah Shin

Sang-hwan Kang

Min-Young Han

Dong-Chul Shin

Minhee Lee

Yong-Hyuk Kim

Young Ah Shin

Taekyung Yoo

Hoechul Jung

So-Young Lee

Sang-Hwan Kang

The present invention provides a novel 2-pyridyl substituted imidazole derivative, or a pharmaceutically acceptable salt or solvate thereof, which selectively inhibits the transforming growth factor-&#x3b2; (TGF-&#x3b2;) type I receptor (ALK5) and/or the activin type I receptor (ALK4); a pharmaceutical composition comprising same as an active ingredient; and a use of the 2-pyridyl substituted imidazole derivative for the manufacture of a medicament for preventing or treating a disease mediated by ALK5 and/or ALK4 receptors in a mammal.

2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors

Disclosed are a gonadotropin releasing hormone receptor antagonist and a pharmaceutical composition including the same, which can be useful in preventing or treating a sex hormone-related disease such as endometriosis, amenorrhea, irregular menstruation, uterine myoma, uterine fibroids, polycystic ovarian disease, lupus erythematous, hypertrichosis, precocious puberty, short stature, acne, alopecia, gonadal steroid-dependent neoplasms, gonadotropin-producing pituitary adenoma, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hyperplasia, contraception, and infertility, as well as Alzheimer disease.

Gonadotropin releasing hormone receptor antagonists, method for the preparation thereof and pharmaceutical composition comprising the same

Growing community of inventors

Yongin-si, South Korea

Euisun Park